An overview of uterine cancer and its management

Expert Review of Anticancer Therapy

Volumn 6, Issue 1, 2006, Pages 33-41

  Carter, Jonathan ^a   Pather, Selvan ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cancer; Corpus; Endometrial; Uterus

Indexed keywords

AROMATASE INHIBITOR; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GESTAGEN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT;

BONE MARROW DEPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL TUMOR; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; COWDEN SYNDROME; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EARLY DIAGNOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INCIDENCE; LAPAROSCOPY; LIVER TOXICITY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MICROMETASTASIS; MORBIDITY; OBESITY; OVERALL SURVIVAL; PEUTZ JEGHERS SYNDROME; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROGNOSIS; RADIATION HAZARD; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SAFETY; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; STANDARD; SURGICAL APPROACH; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; THREE DIMENSIONAL IMAGING; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRASOUND; UNSPECIFIED SIDE EFFECT; UTERUS CANCER; MASS SCREENING; OVARIECTOMY; PATHOLOGY; PEDIGREE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; MASS SCREENING; NEOPLASM STAGING; OVARIECTOMY; PEDIGREE; PROGNOSIS; RISK FACTORS; UTERINE NEOPLASMS;

EID: 33644843287     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.1.33     Document Type: Review

References (102)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10-30 (2005).
2. Parkin D, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J. Clin. 49(1), 33-64 (1999).
3. Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl Cancer Inst. 92(11), 924-930 (2000).
4. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J. Clin. Endocrinol. Metab. 85(6), 2334-2338 (2000).
5. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum. Pathol. 26(11), 1260-1267 (1995).
6. Creasman W. New gynecologic cancer staging. Obstet. Gynecol. 75, 287 (1990).
7. Creasman W, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. J. Epidemiol. Biostats 3(1), 35-61 (1998).
8. Creasman WT, Eddy G. Recent advances in endometrial cancer. Semin. Surg. Oncol. 6(6), 339-342 (1990).
9. Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. Int. J. Gynaecol. Obstet. 83(Suppl. 1), 79-118 (2003).
10. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am. J. Surg. Pathol. 24(9), 1201-1208 (2000).
11. Robertson G. Screening for endometrial cancer. Med. J. Aust. 178(12), 657-659 (2003).
12. Langer RD, Pierce JJ, O'Hanlan KA et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N. Engl. J. Med. 337(25), 1792-1798 (1997).
13. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89(8), 1765-1772 (2000).
14. Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of out-patient endometrial biopsy in the diagnosis of endometrial hyperplasia. Acta. Obstet. Gynecol. Scand. 80(9), 784-793 (2001).
15. Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of out-patient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG 109(3), 313-321 (2002).
16. Smith-Bindman R, Kerlikowske K, Feldstein V, Subak I, Scheidler J, Segal M. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. J. Am. Med. Ass. 280, 1510-1517 (1998).
17. Patsner B, Orr JW Jr, Mann WJ Jr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am. J. Obstet. Gynecol. 162(2), 427-429 (1990).
18. Cowles T, Magrina J, Masterson B, Capen C. Comparison of clinical and surgical staging in patients with endometrial cancer. Obstet. Gynecol. 66, 413-416 (1985).
19. Creasman W, Morrow C, Bundy B, Homesley H, Graham J, Heller P. Surgical pathologic spread patterns of endometrial cancer, a Gynecologic Oncology Group study. Cancer 60, 2035-2041 (1987).
20. Goff B, Rice L. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol. Oncol. 38, 46-48 (1990).
21. Petersen RW, Quinlivan JA, Casper GR, Nicklin JL. Endometrial adenocarcinoma-presenting pathology is a poor guide to surgical management. Aust. NZJ. Obstet. Gynaecol. 40(2), 191-194 (2000).
22. Quinlivan JA, Petersen RW, Nicklin JL. Accuracy of frozen section for the operative management of endometrial cancer. BJOG 108(8), 798-803 (2001).
23. Benedetti-Panici P, Manesch F, Cutillo G et al. Anatomical and pathological study of retroperitoneal nodes in endometrial cancer. Int. J. Gynecol. Cancer 8, 322-327 (1998).
24. Onda T, Yoshikawa H, Mizutani K et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br. J. Cancer 75(12), 1836-1841 (1997).
25. Kilgore LC, Partridge EE, Alvarez RD et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol. Oncol. 56(1), 29-33 (1995).
26. Larson DM, Broste SK, Krawisz BR. Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet. Gynecol. 91(3), 355-359 (1998).
27. Orr JW Jr, Orr PF, Taylor PT. Surgical staging endometrial cancer. Clin. Obstet. Gynecol. 39(3), 656-668 (1996).
28. Kennedy AW, Austin JM Jr, Look KY, Munger CB. The Society of Gynecologic Oncologists Outcomes Task Force. Study of endometrical cancer: initial experiences. Gynecol. Oncol. 79(3), 379-398 (2000).
29. Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol. Oncol. 74(3), 465-467 (1999).
30. Barranger E, Cortez A, Grahek D, Callard P, Uzan S, Darai E. Laparoscopic sentinel node procedure using a combination of patent blue and radiocolloid in women with endometrial cancer. Ann. Surg. Oncol. 11(3), 344-349 (2004).
31. Barranger E, Darai E. Relevance of the sentinel node procedure in endometrial cancer. Gynecol. Oncol. 94(3), 861-862; author reply 862-863 (2004).
32. Barranger E, Fay S, Cortez A, Uzan S, Darai E. Value of the sentinel node biopsy in uterine cancers. Gynecol. Obstet. Fertil. 32(9), 694-702 (2004).
33. Burke T, Levenback C, Tornos C, Morris M, Taylor Wharton J, Gershenson D. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high risk endometrial cancer: results of a pilot study. Gynecol. Oncol. 62, 169-173 (1996).
34. Fersis N, Gruber I, Relakis K et al. Sentinel node identification and intraoperative lymphatic mapping. First results of a pilot study in patients with endometrial cancel Eur. J. Gynaecol. Oncol. 25(3), 339-342 (2004).
35. Holub Z, Jabor A, Lukac J, Kliment L. Laparoscopic detection of sentinel lymph nodes using blue dye in women with cervical and endometrial cancer. Med. Sci. Monit. 10(10), CR587-CR591 (2004).
36. Kim R, Rose PG. Surgical staging of gynecologic malignancies: the role of laparoscopy and sentinel node technology. Surg. Oncol. Clin. N. Am. 14(2), 267-288 (2005).
37. Lelievre L, Camatte S, Le Frere-belda MA et al. Sentinel lymph node biopsy in cervix and corpus uteri cancers. Int. J. Gynecol. Cancer 14(2), 271-278 (2004).
38. Maccauro M, Lucignani G, Aliberti G et al. Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer. Eur. J. Nucl. Med. Mol. Imaging 32(5), 569-574 (2005).
39. Negishi H, Takeda M, Fujimoto T et al. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol. Oncol. 94(1), 161-166 (2004).
40. Niikura H, Okamura C, Utsunomiya H et al. Sentinel lymph node detection in patients with endometrial cancer. Gynecol. Oncol. 92(2), 669-674 (2004).
41. Oehler MK, Fung A, Jobling TW. Advances in the treatment of endometrial cancer. J. Br. Menopause Soc. 11(1), 18-22 (2005).
42. Raspagliesi F, Ditto A, Kusamura S et al. Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. Am. J. Obstet. Gynecol. 191(2), 435-439 (2004).
43. Torne A, Puig-Tintore LM. The use of sentinel lymph nodes in gynaecological malignancies. Curr. Opin. Obstet. Gynecol. 16(1), 57-64 (2004).
44. Cartron G, Leblanc E, Ferron G, Martel P, Narducci F, Querleu D. Complications of laparoscopic lymphadenectomy in gynaecologic oncology. A series of 1102 procedures in 915 patients. Gynecol. Obstet. Fertil. 33(5), 304-314 (2005).
45. Corrado G, Ercoli A, Ferrandina G, Scambia G. Re: A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment by P. Morice et al. Gynecol. Oncol. 98(1), 175; author reply 176 (2005).
46. Magrina JF. Outcomes of laparoscopic treatment for endometrial cancer. Curr. Opin. Obstet. Gynecol. 17(4), 343-346 (2005).
47. Nezhat F, Yadav J, Rahaman J, Gretz H 3rd, Gardner GJ, Cohen CJ. Laparoscopic lymphadenectomy for gynecologic malignancies using ultrasonically activated shears: analysis of first 100 cases. Gynecol. Oncol. 97(3), 813-819 (2005).
48. Obermair A, Manolitsas TP, Leung Y, Hammond IG, McCartney AJ. Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer. Int. J. Gynecol. Cancer 15(2), 319-324 (2005).
49. Papadia A, Remorgida V, Salom EM, Ragni N. Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic oncology. J. Am. Assoc. Gynecol. Laparosc. 11(3), 297-306 (2004).
50. Seracchioli R, Venturoli S, Ceccarin M et al. Is total laparoscopic surgery for endometrial carcinoma at risk of local recurrence? A long-term survival. Anticancer Res. 25(3c), 2423-2428 (2005).
51. Tozzi R, Malur S, Koehler C, Schneider A. Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study. J. Minim. Invasive Gynecol. 12(2), 130-136 (2005).
52. Wong CK, Wong YH, Lo LS, Tai CM, Ng TK. Laparoscopy compared with laparotomy for the surgical staging of endometrial carcinoma. J. Obstet. Gynaecol. Res. 31(4), 286-290 (2005).
53. Yu CK, Cutner A, Mould T, Olaitan A. Total laparoscopic hysterectomy as a primary surgical treatment for endometrial cancer in morbidly obese women. BJOG 112(1), 115-117 (2005).
54. Zapico A, Fuentes P, Grassa A, Arnanz F, Otazua J, Cortes-Prieto J. Laparoscopic-assisted vaginal hysterectomy versus abdominal hysterectomy in Stages I and II endometrial cancer. Operating data, follow-up and survival. Gynecol. Oncol. 98(2), 222-227 (2005).
55. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet. Gynecol. 56(4), 419-427 (1980).
56. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with Stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355(9213), 1404-1411 (2000).
57. Creutzberg CL, van Putten WL, Koper PC et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial Gynecol. Oncol. 89(2), 201-209 (2003)
58. Creutzberg CL, van Putten WL, Koper PC et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 51(5), 1246-1255 (2001).
59. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC et al. Outcome of high-risk Stage IC, Grade 3, compared with Stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J. Clin. Oncol. 22(7), 1234-1241 (2004).
60. Scholten AN, van Putten WL, Beerman H et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized portec trial with central pathology review. Int. J. Radiat. Oncol. Biol. Phys. 63(3), 834-838 (2005).
61. Keys HM, Roberts JA, Brunetto VL et al. A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92(3), 744-751 (2004).
62. Adli M, Mayr NA, Kaiser HS et al. Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer? Int. J. Radiat. Oncol. Biol. Phys. 57(1), 230-238 (2003).
63. Ahamad A, D'Souza W, Salehpour M et al. Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int. J. Radiat. Oncol. Biol. Phys. 62(4), 1117-1124 (2005).
64. Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensch J, Mundt AJ. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 54(5), 1388-1396 (2002).
65. Heron DE, Gerszten K, Selvaraj RN et al. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms small star, filled. Gynecol. Oncol. 91(1), 39-45 (2003).
66. Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JC. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57(2), 516-521 (2003).
67. Molla M, Escude L, Nouet P et al. Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? Int. J. Radiat. Oncol. Biol. Phys. 62(1), 118-124 (2005).
68. Mu X, Olofsson L, Karlsson M, Sjogren R, Zackrisson B. Can photon IMRT be improved by combination with mixed electron and photon techniques? Acta. Oncol. 43(8), 727-735 (2004).
69. Mundt AJ, Lujan AE, Rotmensch J et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1330-1337 (2002).
70. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 56(5), 1354-1360 (2003).
71. Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 48(5), 1613-1621 (2000).
72. van de Bunt L, van der Heide UA, Ketelaars M, de Kort GA, Jurgenliemk-Schulz IM. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: the impact of tumor regression. Int. J. Radiat. Oncol. Biol. Phys. (In press) (2005).
73. Wong E, D'Souza DP, Chen JZ et al. Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies. Int. J. Radiat. Oncol. Biol. Phys. 61(3), 830-841 (2005).
74. Potish R, Twiggs L, Adcock L, Savage J, Levitt S, Prem K. Paraaortic lymph node radiotherapy in cancer of the uterine corpus. Obstet. Gynecol. 65, 251-256 (1985).
75. Rose PG, Cha SD, Tak WK, Fitzgerald T, Reale F, Hunter RE. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 24(2), 229-233 (1992).
76. Sutton G, Axelrod JH, Bundy BN et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with Stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol. Oncol. 97(3), 755-763 (2005).
77. Randall M, Brunetto G, Muss H et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized Phase III trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21(23 Suppl.), 237 (2003).
78. Sagae S, Udagawa Y, Susumu N. Randomized Phase III trial of whole abdominal pelvic radiotherapy vs. cisplatin bases chemotherapy in patients wit intermediate risk endometrial carcinoma. J. Clin. Oncol. 23(Suppl. 16), 455s abstract 5002 (2005).
79. Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am. J. Obstet. Gynecol. 192(5), 1365-1367 (2005).
80. Michener CM, Peterson G, Kulp B, Webster KD, Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J. Cancer Res. Clin. Oncol. 131(9), 581-584 (2005).
81. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22(11), 2159-2166 (2004).
82. Fleming GF, Filiaci VL, Bentley RC et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann. Oncol. 15(8), 1173-1178 (2004).
83. Thigpen J, Blessing J, DiSaia P, Yordan E, Carson L, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 12, 1408-1414 (1994).
84. Despierre E, Moerman P, Vergote I, Amant F. Is there a role for neoadjuvant chemotherapy in the treatment of Stage IV uterine papillary serous carcinoma? Int. J. Gynecol. Cancer (In press) (2005).
85. COSA-NZ-UK Endometrial Cancer Study Groups. Adjuvant medroxyprogesterone acetate in high risk endometrial cancer. Int. J. Gynecol. Cancer 8, 387-391 (1998).
86. Vergote I, Kjorstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 64(5), 1011-1016 (1989).
87. Martin-Hirsch P, Lilford R, Jarvis G. Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. Eur. J. Obstet. Gynecol. Reprod. Biol. 65(2), 201-207 (1996).
88. Fiorica J, Brunetto V, Hanjani P, Lentz S, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A GOG study. Gynecol. Oncol. 92, 10-14 (2004).
89. Thigpen JT, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 19, 364-367 (2001).
90. Whitney C, Brunetto V, Zaino R et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial cancer: A GOG study. Gynecol. Oncol. 92, 4-9 (2004).
91. Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 14(2), 357-361 (1996).
92. Covens A, Thomas G, Shaw P et al. A Phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol. Oncol. 64, 126-129 (1997).
93. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A Phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 78(2), 212-216 (2000).
94. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol. Oncol. 17(1), 85-103 (1984).
95. Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ 157(7), 879-886 (1997).
96. Allsop JR, Preston J, Crocker S. Is there any value in the long-term follow-up of women treated for endometrial cancer? Br. J. Obstet. Gynaecol. 104(1), 122 (1997).
97. Gordon AF, Owen P, Chien PF, Duncan ID. A critical evaluation of follow-up of women treated for endometrial adenocarcinoma. J. Obstet. Gynaecol. 17(4), 386-389 (1997).
98. Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. Int. J. Gynecol. Cancer 15(3), 413-419 (2005).
99. Owen P, Duncan ID. Is there any value in the long-term follow-up of women treated for endometrial cancer? Br. J. Obstet. Gynaecol. 103(7), 710-713 (1996).
100. Shumsky AG, Brasher PM, Stuart GC, Nation JG. Risk-specific follow-up for endometrial carcinoma patients. Gynecol. Oncol. 65(3), 379-382 (1997).
101. Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol. Oncol. 55(2), 229-233 (1994).
102. Tjalma WA, van Dam PA, Makar AP, Cruickshank DJ. The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients. Int. J. Gynecol. Cancer 14(5), 931-937 (2004).